179 related articles for article (PubMed ID: 28769043)
1. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.
Sonego M; Pellizzari I; Dall'Acqua A; Pivetta E; Lorenzon I; Benevol S; Bomben R; Spessotto P; Sorio R; Gattei V; Belletti B; Schiappacassi M; Baldassarre G
Sci Rep; 2017 Aug; 7(1):7104. PubMed ID: 28769043
[TBL] [Abstract][Full Text] [Related]
2. Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.
Lorenzon I; Pellarin I; Pellizzari I; D'Andrea S; Belletti B; Sonego M; Baldassarre G; Schiappacassi M
Cells; 2019 Dec; 9(1):. PubMed ID: 31877751
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
4. Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway.
Chu L; Wang F; Zhang W; Li HF; Xu J; Tong XW
Technol Cancer Res Treat; 2020; 19():1533033820977535. PubMed ID: 33302812
[TBL] [Abstract][Full Text] [Related]
5. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Gambelli A; Nespolo A; Rampioni Vinciguerra GL; Pivetta E; Pellarin I; Nicoloso MS; Scapin C; Stefanatti L; Segatto I; Favero A; D'Andrea S; Mucignat MT; Bartoletti M; Lucia E; Schiappacassi M; Spessotto P; Canzonieri V; Giorda G; Puglisi F; Vecchione A; Belletti B; Sonego M; Baldassarre G
EMBO Mol Med; 2024 May; 16(5):1162-1192. PubMed ID: 38658801
[TBL] [Abstract][Full Text] [Related]
6. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
7. DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Connor JP; Felder M; Kapur A; Onujiogu N
BMC Cancer; 2012 May; 12():176. PubMed ID: 22583667
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
[TBL] [Abstract][Full Text] [Related]
9. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
10. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
11. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
12. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
13. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
15. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
Sonego M; Poletto E; Pivetta E; Nicoloso MS; Pellicani R; Vinciguerra GLR; Citron F; Sorio R; Mongiat M; Baldassarre G
Cells; 2019 Dec; 9(1):. PubMed ID: 31861382
[TBL] [Abstract][Full Text] [Related]
16. Response of Cisplatin Resistant Skov-3 Cells to [Pt(
De Castro F; Benedetti M; Antonaci G; Del Coco L; De Pascali SA; Muscella A; Marsigliante S; Fanizzi FP
Molecules; 2018 Sep; 23(9):. PubMed ID: 30205612
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
18. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
19. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
20. hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer.
Hu XQ; Zhang BY; Hua T
J Int Med Res; 2023 Mar; 51(3):3000605231163780. PubMed ID: 36994850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
